Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Receptos to deliver scientific presentations about RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
Pharmacology and therapeutic potential of interferons.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Cyclophosphamide
Phase 3 Study of RPC1063 in Relapsing MS
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Pregnancy outcomes in patients exposed to interferon beta-1b.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Genzyme’s Lemtrada Approved by the FDA
More to come: humoral immune responses in MS.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.

Pages